Published in Cancer Weekly, January 29th, 2002
Stanford University Medical Center investigator S. Ning and colleagues in the Department of Radiation Oncology recently concluded SU6668 and SU5416 are valuable adjuvants to irradiation therapy for increasing tumor cell death, based on their studies of irradiated mice implanted with SCC VII cells, which express several key angiogenic growth factors as well as their receptors.
The two molecular inhibitors, SU6668 and SU5416, hinder the activity of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.